Sumatriptan Mechanism of Action
Sumatriptan works as a selective 5-HT1B/1D receptor agonist that treats migraine through two primary mechanisms: constricting intracranial blood vessels and inhibiting pro-inflammatory neuropeptide release from trigeminal sensory nerves. 1
Primary Mechanisms
Vascular Effects
Sumatriptan binds with high affinity to 5-HT1B receptors located on intracranial blood vessels, causing cranial vessel constriction 1. This vasoconstriction is:
- Direct and dose-dependent
- Occurs on large cerebral arteries and dural vessels 2
- Reproducible both during and between migraine attacks 3
- Does not significantly affect cerebral blood flow but constricts arteriovenous anastomoses that may dilate during attacks 3
Neurogenic Inflammation Inhibition
The drug acts on 5-HT1D receptors on sensory nerves of the trigeminal system, resulting in inhibition of pro-inflammatory neuropeptide release 1. Specifically:
- Blocks neurogenic dural inflammation 2
- Inhibits release of calcitonin gene-related peptide (CGRP), which is elevated during migraine attacks 3, 4
- Reduces plasma protein extravasation from dural blood vessels 3
- Decreases inflammatory markers including interleukin-1β, tumor necrosis factor-α, and nuclear factor-κB 4
Additional Mechanisms
Recent research reveals more complex actions:
- Modulates ion channels: Suppresses voltage-gated calcium currents and causes hyperpolarizing shifts in potassium channel activation, which may prevent inflammatory mediator-induced sensitization of dural afferents 5
- Central nervous system effects: Modulates c-fos expression in trigeminal nucleus caudalis, indicating inhibition of central trigeminovascular pathway activation 6
Clinical Implications
Important Caveats
- Sumatriptan has poor blood-brain barrier penetration, suggesting its primary site of action is peripheral rather than central 2
- The drug is contraindicated in patients with ischemic vascular conditions, vasospastic coronary disease, uncontrolled hypertension, or significant cardiovascular disease due to its vasoconstrictive properties 7
- Can cause transient blood pressure elevation, including hypertensive crisis 1
Pharmacological Profile
The 5-HT1B/1D receptor selectivity distinguishes triptans from older ergot alkaloids (which are nonselective 5-HT1 receptor agonists) 7. This selectivity provides:
- More predictable therapeutic effects
- Better tolerability profile
- Reduced risk of medication-overuse headaches compared to ergotamines 7
The dual mechanism—both vascular and neurogenic—explains why sumatriptan is effective in 70-82% of patients when given subcutaneously 7, making it the gold standard for acute migraine treatment requiring parenteral therapy 8.